Back to top

Analyst Blog

Palatin Technologies, Inc. (PTN - Snapshot Report) recently announced that the company and its partner, AstraZeneca (AZN - Analyst Report), have halted the development of phase I obesity candidate, AZD2820. AZD2820 is a subcutaneously-administered peptide melanocortin-4 receptor partial agonist. The clinical development of the candidate was stopped after it was suspected that it may cause allergic reactions.

AZD2820’s safety, tolerability, pharmacokinetics and pharmacodynamics were being evaluated in an ascending dose phase I study conducted by AstraZeneca. AstraZeneca planned to enroll 72 obese males for this trial. However, the study was stopped by the Safety Review Committee at AstraZeneca due to the occurrence of the aforementioned serious adverse event. Before the study was discontinued, 11 patients had already completed their dosing schedule.  

We note that this was the second phase I study of AZD2820. The first one was completed in 2011 without any reported incidence of serious adverse events.


In January 2007, Palatin and AstraZeneca entered into an exclusive research collaboration and license agreement for the development of melanocortin receptor drugs for the treatment of obesity, diabetes and related metabolic syndrome. The agreement has been modified several times since then to include more compounds and amend royalty rates and milestone payments.

As per the terms of the agreement, Palatin is eligible to receive mid-to-high single digit royalties on sales of any approved products arising from this collaboration. The research collaboration expired in January 2010 post which AstraZeneca has undertaken all the developmental duties.

Our Recommendation

We currently have a Neutral recommendation on both AstraZeneca and Palatin. While Palatin carries a Zacks #2 Rank (Buy rating) in the short run, AstraZeneca carries a Zacks #3 Rank (short-term Hold rating).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%